Table 3 Subgroup analysis results of esketamine dosage
Subgroup Outcomes | Control | Number of studies | Results of heterogeneity test | Meta analysis results | ||
|---|---|---|---|---|---|---|
P value | I2 | MD or RR (95% CI) | P value | |||
(A) Recovery time | ||||||
0.1–0.15 mg/kg esketamine | NS group | 2 | 0.0003 | 92% | -1.76 (-5.13,1.62) | 0.31 |
0.2–0.3 mg/kg esketamine | NS group | 8 | 0.004 | 67% | -1.03(-1.98,-0.08) | 0.03 |
opioids group | 2 | 0.08 | 68% | -1.35(-2.34,-0.35) | 0.008 | |
0.4–0.5 mg/kg esketamine | NS group | 6 | < 0.001 | 88% | 0.24(-1.87,2.35) | 0.82 |
opioids group | 3 | < 0.001 | 90% | -0.93(-4.15,2.29) | 0.57 | |
0.7–1 mg/kg esketamine | NS group | 2 | 0.008 | 86% | -0.12(-12.67,12.42) | 0.98 |
(B) Propofol dosage | ||||||
0.1–0.15 mg/kg esketamine | NS group | 2 | 0.09 | 66% | -1.31 (-1.64, -0.99) | < 0.001 |
0.2–0.3 mg/kg esketamine | NS group | 5 | < 0.001 | 89% | -1.50(-1.85, -1.16) | < 0.001 |
opioids group | 2 | 0.27 | 17% | -0.79(-0.90, -0.68) | < 0.001 | |
0.4–0.5 mg/kg esketamine | NS group | 4 | 0.003 | 78% | -2.87(-3.69, -2.05) | < 0.001 |
opioids group | 2 | < 0.001 | 99% | -1.47(-2.75, -0.18) | 0.03 | |
0.7–1 mg/kg esketamine | NS group | 2 | 0.44 | 0% | -3.21(-3.80, -2.62) | < 0.001 |
(C) Adverse events | ||||||
0.1–0.15 mg/kg esketamine | NS group | 2 | 0.005 | 87% | 0.74 (0.33, 1.66) | 0.47 |
0.2–0.3 mg/kg esketamine | NS group | 7 | < 0.001 | 83% | 0.58(0.39, 0.85) | 0.006 |
opioids group | 3 | 0.38 | 0% | 0.49(-0.34,0.72) | 0.0002 | |
0.4–0.5 mg/kg esketamine | NS group | 5 | 0.36 | 8% | 0.75(0.60, 0.94) | 0.01 |
opioids group | 4 | < 0.001 | 86% | 0.67(0.56, 0.81) | < 0.001 | |
0.7–1 mg/kg esketamine | NS group | 2 | 0.84 | 0% | 1.32 (1.12, 1.54) | 0.0007 |